Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP9 | P55211 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494650 | 0.82 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL15910713 | 0.76 | PNMT (0.39) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3321993 | 0.76 | GAA (0.40) | MEN1KMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL1997187 | 0.75 | MAPT (0.50) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL7029422 | 0.75 | CASP1 (0.48) | MEN1KMT2ACASP1CASP3CASP4 | |
| SCHEMBL654959 | 0.73 | ALDH1A1 (0.45) | MEN1KMT2ACASP3ALDH1A1MAPT | |
| SCHEMBL3596541 | 0.72 | MAPK1 (0.47) | MEN1KMT2ACASP1CASP3CASP4 | |
| SCHEMBL6291722 | 0.71 | GRIN2B (0.55) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL6296037 | 0.71 | DRD4 (0.54) | ALDH1A1MAPK1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL8186681 | 0.70 | GRIN2B (0.54) | ALDH1A1MAPK1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513262-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20070238875-A1 | HETEROCYCLIC COMPOUNDS | LEO OSPREY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070015775-A1 | HETEROCYCLIC COMPOUNDS | LEO OSPREY LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| CN-1134438-C | Bicyclic heteroaromatic compounds, preparation method and use thereof | �ձ���ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| CN-1292788-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 2001-04-25 | — | — | CN | disclosed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | disclosed |
| CN-1230187-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 1999-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | MEN1 215/4885KMT2A 385/4885CASP1 1167/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | MEN1 3421/4885KMT2A 2440/4885CASP1 4290/4885 |
| US-20070015775-A1 | HETEROCYCLIC COMPOUNDS | CCNH, SDHA, CYP1A2 | MEN1 244/4885KMT2A 1511/4885CASP1 1998/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MEN1 2579/4885KMT2A 1174/4885CASP1 3042/4885 |
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | MEN1 2117/4885KMT2A 1161/4885CASP1 1250/4885 |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ABL1, ERBB2, CDK2 | MEN1 1942/4885KMT2A 693/4885CASP1 2976/4885 |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | ABL1, ERBB2, SRC | MEN1 2579/4885KMT2A 1174/4885CASP1 3042/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MEN1 2579/4885KMT2A 1174/4885CASP1 3042/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MEN1 2579/4885KMT2A 1174/4885CASP1 3042/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | MEN1 3232/4885KMT2A 2665/4885CASP1 1922/4885 |
| US-20070238875-A1 | HETEROCYCLIC COMPOUNDS | CCNH, SDHA, CYP1A2 | MEN1 244/4885KMT2A 1511/4885CASP1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.